Previous 10 | Next 10 |
WARMINSTER, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13,...
Arbutus Biopharma Corporation (ABUS) Q2 2019 Results Earnings Conference Call August 05, 2019, 08:45 AM ET Company Participants Pam Murphy - IR Consultant William Collier - President, CEO David Hastings - CFO & CAO Gaston Picchio - Chief Development Officer Michael Sofia ...
Arbutus Biopharma ( ABUS ) Q1 results : Revenues: $0.7M (-41.7%). More news on: Arbutus Biopharma Corporation, Healthcare stocks news, Earnings news and commentary, , Read more ...
Arbutus Biopharma (NASDAQ: ABUS ): Q2 GAAP EPS of -$0.46 misses by $0.08 . More news on: Arbutus Biopharma Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
- Appointed William Collier , with decades of leadership experience in antivirals, President & CEO - Announced preliminary Phase 1a/1b clinical trial results demonstrating that AB-506 is a potent capsid inhibitor in subjects with chronic hepatitis B - Initiated dosing in he...
WARMINSTER, Pa., July 29, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its second quarter financial results, conference call and webcast for Monday, Aug...
Arbutus Biopharma (NASDAQ: ABUS ) perks up 3% after hours in reaction to positive data from a Phase 1a/1b clinical trial evaluating HBV capsid inhibitor AB-506 in healthy volunteers and two cohorts with chronic hepatitis B virus (HBV) infection. More news on: Arbutus Biopharm...
Results demonstrate that AB-506 is a potent capsid inhibitor Phase 1a/1b clinical trial to continue with the enrollment of further cohorts Conference call and webcast scheduled today at 4:45 pm ET WARMINSTER, Pa., July 15, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporati...
Arbutus Biopharma (NASDAQ: ABUS ) has sold a part of its royalty interest in future global sales of Alnylam Pharmaceuticals' ONPATTRO (patisiran), approved by the U.S. and Europe in August 2018 for polyneuropathy caused by hATTR, to an Ontario, Canada-based pension plan called OMERS. Mor...
- Arbutus to receive $20 million in gross proceeds before advisory fees while retaining significant downstream economics - Runway extended with non-dilutive capital WARMINSTER, Pa., July 02, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an indust...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...